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THE SPECIFIC immunologic non-reactivity to allo-grafts that was first produced in fetal or neonatal mice 
by Billingham, Brent, and Medawar,l and. ultimately, in 
human bone marrow recipients2- 5 has remained enigmatic 
for nearly a half century. Without first understanding this 
"acquired tolerance," and. especially, the "acceptance" of 
organ allografts it is folly to dream of a future that includes 
xenotransplantation. 
Beginning in 1992.6 we have developed an explanation 
for successful transplantation of allografts that, if valid, 
could guide investigators directly to the objective of clinical 
xenotransplantation. A central tenet of our proposal is that 
immune reactivity or non-reactivity (tolerance) to trans-
planted tissues and organs. to microorganisms, and to all 
other antigens (including self), is governed by the migration 
and localization of the antigen.7 Evidence supporting the 
latter conclusion has been obtained from investigations of 
the previously unsuspected chimerism that occurs after 
organ transplantation6•8 .9 and from observations following 
experimental and clinical infections. 10-12 
THE MICROCHIMERISM DISCOVERIES 
In 1992, sparse but widely distributed multilineage donor 
leukocytes (microchimerism) were found in the blood or 
tissues of 30 of 30 human kidney and liver recipients whose 
allografts had functioned for as long as 30 years posttrans-
plantation.6.8·9.13 Because committed leukocytes have a 
limited life span, this could only mean that precursor or 
stem cells are included in the burst of donor leukocytes that 
is briefly detectable in recipient blood following organ 
transplantation.8 
In human liver and intestinal recipients the donor con-
tribution to the circulating host white blood cells peaks at 
10% to 20% after about 10 days, at the same time as these 
"passenger leukocytes" disappear from the graft. 14.15 The 
same thing on a smaller scale is seen after transplantation of 
organs like the kidney and heart that contain fewer leuko-
cytes. 
These discoveries suggested an explanation for 2 enig-
matic observations made 30 years earlier upon which the 
development of clinical organ transplantation at a practical 
level was based. In patients treated with azathioprine plus 
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dose maneuverable prednisone. it had been found in 1962 
to 1963, first, that kidney rejection was a consistently 
reversible phenomenon, and. second. that renal allografts 
could systematically self-induce variable degrees of donor 
specific tolerance. 16 It was soon learned that the same thing 
happened with other transplanted organs17, and could be 
observed in many animal models without the need for 
immunosuppression (summarized in Starzl et aI18). 
THE HISTORICAL LINKAGE TO INFECTION 
Early workers in transplantation had recognized the 
resemblance of allograft rejection to the response against 
infections, such as tuberculosis, that were associated with 
delayed hypersensitivity.19 With the demonstration of the 
MHC-restricted mechanisms of adaptive infectious immu-
nity by Zinkernagel and Doherty in 1973 and 1974,20.21 it 
seemed obvious that allograft rejection must be analogous 
to the immune response to this kind of infection. 
Typically, the microorganisms that generate an adaptive 
immune response are intracellular with low or no cytopathic 
qualities. Host cytolytic T lymphocytes recognize as targets 
only those cells displaying host MHC antigen plus relevant 
peptide of the infectious agent. However, because elimina-
tion of all the infected cells could disable or even kill the 
host, mechanisms have evolved that can temper or termi-
nate the immune response, allowing both host and patho-
gen to survive. 
After infection with widely disseminated non-cytopathic 
microorganisms (eg, the common hepatitis viruses), the 
antigen load rapidly increases in the so-called latent period 
(Fig 1, second panel). The delayed development and sub-
sidence of effector T cells. usually results in efficient. 
although rarely, if ever, complete, elimination of the patho-
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Fig 1. Potential outcomes af--
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ter infection with noncytopathic 
microorganisms and analogies 
(expressed as rejection or graft-
versus-host disease) to organ 
and bone marrow transplanta-
tion. The horizontal axis denotes 
time. The vertical axis shows the 
magnitude of the viral load (v, 
solid line), and the host immune 
response (IR, dashed line). (By 
permission of New England 
Journal of Medicine, 339:1905, 
1998) 
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gen (Fig 1, second panel). These events are similar to those 
of irreversible rejection in the unmodified or ineffectively 
treated organ recipient. 
Alternatively, however. such infections may lead to a 
continuously high antigen load and to an antigen specific 
immunologic collapse, resulting in an asymptomatic carrier 
state (Fig 1, left panel). This is equivalent to unqualified 
acceptance of an allograft. 
Between these 2 extremes leading to a carrier state (left 
panel) and protective immunity (second panel). an unre-
lenting immune response (dashed line) to a persistent 
infectious agent as shown in Fig 1 third panel can result in 
serious immunopathology (eg, chronic active hepatitis 
caused by a B or C virus infection). By analogy, this is 
equivalent to chronic rejection. or uncommonly GVHD 
after liver transplantation (see later). 
MECHANISMS OF NON-REACTIVITY 
The biologic safety valve that permits the compromise 
outcomes in the first and third panels of Fig 1 consists of 
only 2 mechanisms, both regulated by antigen migration 
and localization.7 One mechanism is clonal exhaustion 
leading to clonal deletion. The other is immune indiffer-
ence. 
CLONAL EXHAUSTION/DELETION 
Thirty years ago, we postulated that the fundamental 
mechanism of organ engraftment under immunosuppres-
sion was proliferative exhaustion and deletion of a donor 
specific clone. ~O and cited an even earlier prediction by 
Schwartz and DameshekZ3 that this might occur. Clonal 
exhaustion was generally discounted. however. in part be-
cause it remained only a theoretical possibility until its 
experimental verification by Webb. Morris, and Sprent in 
1990.24 Since then. clonal exhaustion has been demon-
strated in many infectious. transplantation. and other mod-
ds as recently summarized by Bishop et al. 25 
In these diverse models. a subpopulation of T cells is 
induced by the antigen within a few days. end differentiates 
to effector cells. and disappears. Death of the activated cells 
by interleukin deprivation and other mechanisms associated 
with apoptosis seem to be involvedK~"·OT Although this 
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purging is thymus dependent in many mammalian species, 
deletion also occurs in the peripheral lymphoid organs,28 
whieh may be the principal if not the sole sites in human 
organ recipients. 18 
Clonal exhaustion as the primary mechanism of organ 
allograft acceptance was ignored in the literature for more 
than 2 decades beginning in 1970 because of failure to 
understand the role of the organ's passenger leukocytes. 
These donor cells of bone marrow origin have long been 
known to be the principal immunogenic component of 
allografts,29,3o a quality widely attributed to their expression 
of major histocompatibility complex class II and/or costimu-
latory molecules.31 Consequently, the disappearance of 
passenger leukocytes from long surviving transplanted tis-
sues and organs was assumed, first, to be an obligatory 
condition for allograft acceptance. and. second, to connote 
the selective destruction of these donor cells by the recipi-
ent immune system with selective sparing of the specialized 
parenchymal cells. 
With the latter disorienting premise. organ allograft 
acceptance appeared to be different than the chimerism-
dependent acquired neonatal tolerance of Billingham. 
Brent. and Medawar l and its clinical analogue. bone mar-
row transplantation.2- 5 Consequently, numerous chimerism-
exclusionary hypotheses for organ allograft acceptance sprang 
up involving immune regulatory cells, cytokine profile 
changes, and various antibody states.7 A popular current 
theory is that T cells, both in lymphoid organs and in the 
periphery, are turned-off (Uanergized") if they encounter 
appropriately presented antigen in the absence of a second 
signal provided by costimulatory (B7) molecules. 
Contrary to these hypotheses. the discovery of microchi-
merism in organ recipients. has made it possible to explain 
allograft acceptance by" ... [widespread] responses of co-
existing donor and recipient immune cells. each to the 
other. causing reciprocal clonal expansion. followed by 
peripheral clonal deletion [clonal exhaustion]. "0 If some 
degree of reciprocal clonal exhaustion is not induced and 
maintained. one cell population will destroy the other. or 
both may be destroyed togetherK"-4II~ 
Following organ transplantation. the dominant host sys-
tem (Fig 2) usually rejects the graft. but serious or lethal 
GYHD is not rare after transplantation of leukocyte-rich 
-
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Fig 2. Contemporaneous host-versus-graft (HVG) and graft-
versus-host (GVH) reactions after transplantation. Failure is 
defined as the inability to control one of the reactions, or 
sometimes both. Acute reciprocal clonal exhaustion after suc-
cessful transplantation is maintained subsequently by chimer-
ism-dependent low-grade stimulation of both leukocyte popula-
tions that may wax and wane. (By permission of New England 
Journal of Medicine, 339:1905, 1998) 
organs like the liver.s In contrast. weakening of host 
immune reactivity by cytoablation prior to bone marrow 
transplantation transfers dominance to the donor system. 
Consequently, GVHD is the most common complication in 
bone marrow recipients. but the graft may be rejected 
instead, or simultaneously.6-8.18 
"What governs clonal exhaustion?" It is well known that 
immune activation against spreading non-cytopathic patho-
gens requires their migration to and localization in lym-
phoid organs. IO•11 The similar lymphoid-oriented traffic of 
passenger leukocytes has been well documented.32- 34 It is 
self evident that this pattern of antigen migration. which is 
the essential basis of host sensitization, also is the prereq-
uisite for specific immunologic tolerance by clonal exhaus-
tion. 
IMMUNE INDIFFERENCE 
However. survival of the antigen may be enhanced by a 
second non-tolerogenic mechanism. called "immune indif-
ference.'·7.IO-12 Like clonal exhaustion. immune indiffer-
ence also is controlled by antigen migration and localiza-
tion. 
Primary Immune Indifference. Pure examples of immune 
indifference are provided by the rabies and wart viruses (Fig 
1, right panel) that elicit little or no immune rcsponse by 
avoiding migration through, or to. host lymphoid organs. 
This situation has been mimickcd in many transplant mod-
cis by depletion of donor leukocytes from allografts:15.Jfi 
Although allograft survival is thereby prolonged. donor 
specific tolerance does not develop. Rejection can bc 
readily precipitated with an injection of donor Icuko-
cvtesJ5 .36 as first shown 30 vears UlW bv Elkins and Gutt-
~an:Do ' -, 
SecondalV Immune IlldiflerellCt:. Such dc novo nonrc-
sponsiveness is not seen in thc usual setting of clinical organ 
transplantation. but it may evolve secondarily.b-K As also 
occurs following a widespread noncytopathic infection. Ie 
migratory donor leukocytes that have not been eliminated 
hy passage through lymphoid organs leave the lymphoid 
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compartment after about 2 weeks. having induced various 
stages of antigen specific exhaustion that is probably almost 
never complete or absolutely irreversible. 
In animal models. and also in humans, the principal 
donor leukocyte population has secondarily migrated by 
100 days posttransplantation to nonlymphoid sites, such as 
skin and heart (Fig 3), making it increasingly difficult to 
detect microchimerism in random blood samples or in 
biopsies of lymphoid organs. In the meanwhile, the leuko-
cyte-depleted organ allograft becomes progressively less 
immunogenic. Maintenance clonal exhaustion apparently 
occurs subsequently by leakage of donor leukocytes from 
the non-lymphoid to the lymphoid compartment (Fig 3).7 
Although the consequent balance between antigraft im-
munity and clonal exhaustion has been difficult to quantify 
in transplantation models, it has been demonstrated by 
Ohashi and Zinkernagel in transgenic mice whose pancre-
atic islets express viral antigens and are destroyed (with 
resulting diabetes) by the induction of high, but not by low 
level, virus specific crL activity.37.38 
THE COLLABORATION OF MECHANISMS 
Organ Transplantation. With clonal exhaustion and im-
mune indifference in combination, both regulated by the 
migration and localization of antigen, 4 inter-related events 
must occur close together if organ transplantation is to 
succeed:6 -!! clonal exhaustion of the recipient antidonor 
immune response, reciprocal deletion of the donor immu-
nocyte population. maintenance clonal deletion, and loss of 
~~-:KK 
...::::::; ,--
Nonlymphoid Tissue § \_ 
Localization ~ f~_-~----~--------_b~ __ I 
..::'::3"""" ~ -=-
-= I =. 
-- .-
{: == -==;o~; a :~1i""~ 
== . 8 K~--= 
I~ • y ~ 
~ • - ..::::::= ~ • -' I '.= ~y . ~ ~- ' '\ 
. 
t 
3 
-months 
yDoK~ - - -=--=='( ~ J 
L-.-_____ d~K ~ &:1 
Lymphoid Tissue t;7 ~Ds 
, 
• I 
Localization ( -D~/Km .... _ 
"D~ •. • ,,;:..;:::;a-,JIt 
DtDrD~"I-
Fig 3. The distribution of donor leukocytes n 3 months after 
organ transplantation (here. a kidney). With the nearty complete 
departure from the allograft of these cells reducing the organ's 
immunogenlcity, they are replaced by reCipient leukocytes. Note 
the eventual dominance of chimerism in the non-lymphoid 
organs (skin. heart. and liver shown), and the communication 
between the non-lymphOid and lymphoid (spleen. thymus. 
lymph nodes. and bone marrow) compartments. 
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Table 1. Effectors Involved in Response to Cytopathic 
Parasites and Discordant Xenogratts 
The First Une of Defense 
1. Interferons 
2. Macrophages 
3. "(18 T cells 
4. Natural killer (NK) cells 
5. B cells 
Non-Specific or Less Specific Effectors 
1. Complement 
2. Early interleukins 
3. Phagocytes 
organ immunogenicity by in situ passenger leukocyte deple-
tion. 
Donor leukocyte chimerism is critical to these events. 
However, the significance of microchimerism following 
organ transplantation has been questioned (summarized 
in Woods and Sachs39) because, as we have empha-
sizedo-8.18.40 donor leukocytes may be detectable during 
rejection, are often not detectable in individual blood or 
tissue samples in patients bearing stable allografts. and 
cannot, therefore, be used to guide drug weaning. These 
observations are readily fitted into the concept of various 
balanced states that may vary with time and according to 
antigen migration and localization. As we concluded in our 
1992 Lancet report,6 and, again, recently" ... donor leu-
kocyte chimerism is a prerequisite for, but neither synony-
mous with nor a consequence of, the evolution of organ 
allograft acceptance under clinicallv relevant circum-
stances."? -
Bone Marrow Transplantation. Conventional bone mar-
row transplantation is. not only a mirror image of the events 
after organ transplantation,11\.41 but also governed by anti-
gen migration and localization.? Although pre transplant 
cytoablation renders the recipient subject to GVHD. the 
host leukocytes are not all eliminated. The weak host versus 
graft reaction mounted by those recipient cells that remain. 
and by the parallel GVH reaction of the donor cells, can 
eventually result in reciprocal tolerance. 
SELF NON/SELF DISCRIMINATION 
We have proposed that the principle of immune gover-
nance by antigen migration and localization applies to all 
immune reactions and at all stages of life.7 Because the 
fetus possesses T cell immune function in the very early 
stages of its development. antigen migration and localiza-
tion can he viewed as the basis for the ontogeny of 
self/non-self discrimination during fetal development in the 
same way as it is for acquired tolerance in later life. 
Autoimmune diseases would then reflect unacceptable 
postnatal perturbations of the prenatally established local-
ization of self antigens in non-lymphoid versus lymphoid 
tissues. ~ 
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RELEVANCE TO XENOTRANSPLANTATlON 
The migration/localization paradigm predicts what will 
be required to make xenotransplantation feasible. 42 There 
is no MHC-restricted safety valve for cytopathic microor-
ganisms that are typically extracellular and generate the full 
resources of the innate as well as the adaptive immune 
system. 7.10-12 This explosive response is provoked by xeno-
grafts expressing the Gal-a Gal epitope, an epitope that 
also is found on numerous bacteria, protozoa, and viruses. 
Disarming only one of the listed effector mechanisms of 
innate immunity (Table 1) to prevent hyperacute xenograft 
rejection (eg, by inserting human complement regulatory 
genes into pigs) without changing or eliminating the xeno-
geneic epitope will not allow the clinical use of discordant 
animal donors. 
To avoid the devastating consequences of these effectors. 
additional g~netic manipulation will be required. whereby 
antigens are eliminated. or equivalent human genes are 
introduced. Gene knockout procedures have not yet been 
done in the pig-the animal most commonly targeted as a 
xenograft donor. However. using molecular technologies. 
some of which already have been shown to be applicable in 
pigs, the team of Osman, Sandrin, and McKenzie et al43 in 
Australia has been able to reduce cell-surface expression of 
the Gal-a Gal gene product in cultured African green 
monkey fibroblasts (so called COS cells) to negligible levels. 
The experiments were staged. As a first step, the COS cells, 
which normally do not express the Gal-a Gal epitope, were 
transfected with the Gal cDNA. Because these transfected 
COS cells now presented a Gal-a-Gal target, they were 
vigorously lysed by the antibodies in human serum (Fig 4). 
The anti-Gal lysis was reduced, but not eliminated, by 
transfection of the altered COS cell with human a-galacto-
sidase, which cleaves off a-linked galactosyl residues of the 
target epitope (Fig 5). Because this exposes subterminal 
saccharides (ie, N-acetyl lactosamine), to which there also 
are "natural" human antibodies. lysis is only reduced. 
However. the additional insertion of an a( 1,2) fucosyltrans-
ferase gene resulted in the substitution of Gal-a Gal with 
the nonimmunogenic H substance (ie. the universally tol-
erated a blood group antigen). Thus. the double transfec-
gen. prOduct 
Gal-a-Gal 
Transgene 
Transtected COS' Cell 
• African green monkey 
fibrOblast 
~ A ···········V·. ,".",' 
·r" ,.:.:'" ; 
.. ¢?&Y) 
~K: ... : ......... . 
cJv 
Lysed by human serum 
Fig 4. COS cells are lysed by human serum a.fter their trans-
fection With the Gal-a (1.3) Gal gene (see text). (By permission of 
J Am Coli Surg. 186:383. 1998) 
P. 
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• 
Added transfaction 
of a-galactosidase m 
• 
Reduced lysis 
by human serum 
Fig 5. Insertion of a-ga.lactosidase gene diminishes. but does 
not eliminate. the lysis shown in Fig 1 (see text). (By permission 
of J Am Coli Surg. 186:383. 1998) 
tion (galactosidase plus fucosyltransferase) completely 
eliminated complement-mediated lysis of the COS cells 
(Fig 6). 
The a-galactosidase gene has not yet been transfected in 
pigs. but this has been accomplished with the a-fucosyl-
transferase gene by John Logan and associates of the 
Nextran Corporation in collaboration with colleagues at 
Duke University.44 Stable double transfection in pigs would 
seem to be only a matter of time. Thus. far from being 
bleak. the future of xenotransplantation is brighter than at 
any previous time because what must be done to succeed 
has become remarkably clear. 
Rules must be followed that have been established by 
coevolution of the host-parasite relationship. We have 
already learned empirically with allotransplantation how to 
work around. or. more accurately. work with. the defense 
mechanisms developed by nature to control noncytopathic 
infections. These strategies will not work for xenografts 
whose antigens are recognized by the immune system as 
cytopathic microorganisms. Alteration of animal antigens 
so the organs resemble the less threatening noncytopathic 
pathogens will be the key to success. 
Added a-galactosidase I1l 
and 
Fucosyl transferase :::1 
No lysis by 
h'Jman serum 
Fig 6. Additional insertion of the a( 1 .2)fucocyl transferase gene 
converts the xenogeneic Gal-a (1.3) Gal antigen to the H (0. or 
universal donor) antigen and eliminates lysis (see text). (By 
permission of J Am Coli Surg. 186:383.1998) 
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